Skip to Main Content

Why the Janssen/Johnson & Johnson Pause Should Make You Feel Safer


Thomas G. McGinn, MD, MPH System Executive Vice President, CommonSpirit Health

On Tuesday, April 13, the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) jointly announced a recommendation to pause administration of the Janssen/Johnson & Johnson (J&J) vaccine as it undergoes further investigation for rare blood clotting events.

Publish Date: 

Tuesday, May 25, 2021

News

Reflecting on a devastating milestone: Over one million lives lost to COVID-19

MAY 20, 2022

Dr. Thomas McGinn, CommonSpirit Executive Vice President, Physician Enterprise, reflects on one million lives lost to COVID-19.

Read More Additional information about Reflecting on a devastating milestone: Over one million lives lost to COVID-19

CommonSpirit Health Announces FY2022 Q3 Results

MAY 13, 2022

CommonSpirit Health has released financial results for its fiscal year 2022 third quarter.

Read More Additional information about CommonSpirit Health Announces FY2022 Q3 Results

CNO Kathy Sanford: Our approach to nursing must change

MAY 10, 2022

Chief Nursing Officer Kathy Sanford discusses how CommonSpirit Health is changing our approach to nursing by taking proactive steps to support nurses through their career continuum and shape the future workforce.

Read More Additional information about CNO Kathy Sanford: Our approach to nursing must change